PRAX vs. BCYC, NUVB, PHAT, DNTH, WVE, SVRA, ORIC, PHAR, LBPH, and COGT
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Bicycle Therapeutics (BCYC), Nuvation Bio (NUVB), Phathom Pharmaceuticals (PHAT), Dianthus Therapeutics (DNTH), Wave Life Sciences (WVE), Savara (SVRA), ORIC Pharmaceuticals (ORIC), Pharming Group (PHAR), Longboard Pharmaceuticals (LBPH), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical preparations" industry.
Bicycle Therapeutics (NASDAQ:BCYC) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
Bicycle Therapeutics presently has a consensus price target of $47.88, suggesting a potential upside of 119.41%. Praxis Precision Medicines has a consensus price target of $103.00, suggesting a potential upside of 102.84%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe Bicycle Therapeutics is more favorable than Praxis Precision Medicines.
Praxis Precision Medicines has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Bicycle Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.
Bicycle Therapeutics has a net margin of -669.72% compared to Bicycle Therapeutics' net margin of -5,037.88%. Praxis Precision Medicines' return on equity of -57.80% beat Bicycle Therapeutics' return on equity.
Bicycle Therapeutics received 98 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 68.39% of users gave Bicycle Therapeutics an outperform vote while only 58.33% of users gave Praxis Precision Medicines an outperform vote.
In the previous week, Bicycle Therapeutics had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Bicycle Therapeutics and 5 mentions for Praxis Precision Medicines. Bicycle Therapeutics' average media sentiment score of 0.56 beat Praxis Precision Medicines' score of 0.31 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 10.2% of Bicycle Therapeutics shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Bicycle Therapeutics beats Praxis Precision Medicines on 13 of the 18 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
